ProfileGDS5678 / 1452137_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 73% 72% 72% 72% 70% 69% 70% 68% 74% 73% 71% 73% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5777972
GSM967853U87-EV human glioblastoma xenograft - Control 24.7485573
GSM967854U87-EV human glioblastoma xenograft - Control 34.6113772
GSM967855U87-EV human glioblastoma xenograft - Control 44.6330172
GSM967856U87-EV human glioblastoma xenograft - Control 54.6129272
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3537270
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2858969
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3727370
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1980368
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9131274
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6542573
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.5099671
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7589873
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.094176